Hemodialysis Patients with Hepatitis C Infection Are Not Receiving the New Antiviral Medications

American Journal of Nephrology

Volumn 41, Issue 4-5, 2015, Pages 302-

  Goodkin, David A ^a,b   Bieber, Brian ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DASABUVIR; INTERFERON; LEDIPASVIR; PARITAPREVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; OLIGOPEPTIDE;

ANEMIA; AUSTRALIA; DEPRESSION; DISEASE SEVERITY; FATIGUE; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; KIDNEY TRANSPLANTATION; LETTER; MAJOR CLINICAL STUDY; MORTALITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; CLINICAL PRACTICE; COMPLICATION; HEPATITIS C, CHRONIC; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; OLIGOPEPTIDES; PRACTICE PATTERNS, PHYSICIANS'; RENAL DIALYSIS; SIMEPREVIR;

EID: 84937965999     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000432408     Document Type: Letter

References (4)

1. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M: Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405-412.
2. Kidney Disease; Improving Global Outcome: KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 109:S1-S99.
3. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ: The dialysis outcomes and practice patterns study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57(suppl 74):S74-S81.
4. Pollack A: Sales of new hepatitis C drug soar to 10.3 billion, straining budgets. The New York Times February 4, 2015, p B2.